<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68820">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01905540</url>
  </required_header>
  <id_info>
    <org_study_id>SPD602-111</org_study_id>
    <nct_id>NCT01905540</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt)</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, 3-Period, Relative Bioavailability Study Comparing the Pharmacokinetics of SSP-004184AQ (Magnesium Salt) to SSP-004184SS (Disodium Salt) Each Administered as a Single Dose and as Two Doses of SSP-004184 (Free Acid) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the relative bioavailability of the new SSP-004184SS capsule
      formulation compared to the original SSP-004184AQ drug plus excipients formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area Under the Steady-state Plasma Concentration-time Curve (AUC) of SSP-004184 After One Dose</measure>
    <time_frame>Over 120 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of SSP-004184 After One Dose</measure>
    <time_frame>Over 120 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Steady-state Plasma Concentration-time Curve (AUC) of SSP-004184 After Two Doses</measure>
    <time_frame>Over 120 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of SSP-004184 After Two Doses</measure>
    <time_frame>Over 120 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SSP-004184AQ (single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg/kg (oral capsule form) given once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSP-004184SS (single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21.8 mg/kg (oral capsule form) given once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSP-004184AQ (2 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSP-004184SS (2 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21.8 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSP-004184AQ</intervention_name>
    <description>Magnesium salt</description>
    <arm_group_label>SSP-004184AQ (single dose)</arm_group_label>
    <arm_group_label>SSP-004184AQ (2 doses)</arm_group_label>
    <other_name>SPD602</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSP-004184SS</intervention_name>
    <description>Disodium salt</description>
    <arm_group_label>SSP-004184SS (single dose)</arm_group_label>
    <arm_group_label>SSP-004184SS (2 doses)</arm_group_label>
    <other_name>SPD602</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years

          -  Must be considered &quot;healthy&quot;.

          -  Serum ferritin &gt;20ng/mL, hemoglobin &gt;125g/L and erythrocyte indices within normal
             range

        Exclusion Criteria:

          -  Subject has a clinically significant history or a disorder detected during the
             medical interview/physical examination at the Screening Visit or any other medical
             condition that is capable of altering the absorption, metabolism, or elimination of
             drugs

          -  Acute illness, as judged by the investigator, within 2 weeks of Day 1 of Treatment
             Period 1.

          -  Known or suspected intolerance or hypersensitivity to the investigational products,
             closely related compounds, or any of the stated ingredients.

          -  Subject has a history of thyroid disorder that has not been stabilized on thyroid
             medication or treatment within 3 months

          -  History of alcohol or other substance abuse within the last year.

          -  A positive screen for alcohol or drugs of abuse at the Screening Visit.

          -  Confirmed systolic blood pressure &gt;139mmHg or &lt;89mmHg, and diastolic blood pressure
             &gt;89mmHg or &lt;49mmHg.

          -  Twelve-lead ECG demonstrating QTc &gt;450msec at screening.

          -  Routine consumption of more than 2 units of caffeine per day or subjects who
             experience caffeine withdrawal headaches.

          -  Male subjects who consume more than 3 units of alcohol per day. Female subjects who
             consume more than 2 units of alcohol per day.

          -  A positive HIV antibody screen, HBsAg, or HCV antibody screen.

          -  Use of tobacco in any form (eg, smoking or chewing) or other nicotine-containing
             products in any form (eg, gum, patch) within 30 days prior to Day 1 of Treatment
             Period 1.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Lasseter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Pharmacology of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 4, 2013</lastchanged_date>
  <firstreceived_date>July 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
